PA5-22976

antibody from Invitrogen Antibodies

Targeting: LDLR LDLCQ2

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-22976

Provider

Invitrogen Antibodies

Product name

LDLR Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

This antibody is predicted to react with monkey based on 100% sequence homology. This antibody has 92% sequence homology with mouse.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics.

Taiarol L, Bigogno C, Sesana S, Kravicz M, Viale F, Pozzi E, Monza L, Carozzi VA, Meregalli C, Valtorta S, Moresco RM, Koch M, Barbugian F, Russo L, Dondio G, Steinkühler C, Re F
Cancers 2022 Jun 16;14(12)

---

The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial.

Feldt M, Menard J, Rosendahl AH, Lettiero B, Bendahl PO, Belting M, Borgquist S
Cancer & metabolism 2020 Nov 23;8(1):25

---

Development of an LDL Receptor-Targeted Peptide Susceptible to Facilitate the Brain Access of Diagnostic or Therapeutic Agents.

André S, Larbanoix L, Verteneuil S, Stanicki D, Nonclercq D, Vander Elst L, Laurent S, Muller RN, Burtea C
Biology 2020 Jul 11;9(7)

---

Dysregulated Lipid Transport Proteins Correlate With Pathogenesis and Outcome in Severe Alcoholic Hepatitis.

Maras JS, Das S, Bhat A, Kumar Vyas A, Yadav G, Chaudhary S, Sukriti S, Gupta AC, Bihari C, Mahiwall R, Sarin SK
Hepatology communications 2019 Dec;3(12):1598-1625

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry analysis of LDLR in HepG2 cells. Samples were incubated in LDLR polyclonal antibody (Product # PA5-22976) followed by DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of LDLR was performed using 90% confluent log phase Caco-2 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with LDLR Polyclonal Antibody (Product # PA5-22976) at 1:100 dilution in 0.1% BSA, incubated at 4 degrees celsius overnight, and then labeled with Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Product # A32790), (1:2000 dilution), for 45 minutes at room temperature (Panel a: Green). Nuclei (Panel b: Blue) were stained with Hoechst 33342 (Product # H1399). F-actin (Panel c: Red) was stained with Alexa Fluor™ Plus 647 Phalloidin (Product # A30107, 1:2000 dilution). Panel d represents the merged image showing membranous and cytoplasmic localization. Panel e represents control cells with no primary antibody to assess the background. The images were captured at 40X magnification in CellInsight CX7 LZR High-Content Screening (HCS) Platform (Product # CX7A1110LZR) and externally deconvoluted (D.Sage et al. / Methods 115 (2017) 28–41).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 Quantitative proteomic analysis identifies significantly down-regulated lipid transporter proteins in SAH. (A) Partial list of proteins differentially regulated (>1.5-fold; P < 0.05) between SAH, AC, HC, and its GO analysis, which documents enrichment of lipid transporters in SAH. (B) KEGG enrichment analysis of the up-regulated (n = 32) and down-regulated (n = 176) proteins in patients with SAH represents significant ( P < 0.05) enrichment. (C) Plasma level of PON1 was down-regulated in patients with SAH (median, 23.2; range, 2.3-139.4) compared to those with AC (median, 44.7; range, 25.8-131) and HC (median, 139.5; range, 46.6-196.0) ( P < 0.05). (D) Plasma level of apolipoproteins (APOB, APOE, APOA1, APOA2, APOC1, APOC3) in SAH compared to AC and HC ( P < 0.05 is significant). (E) IHC showing expression of PON1, LDL, CD36, SRA1, ABCA1, and ABCG1 in SAH (n = 5) and AC (n = 5). For all IHC analyses, relative quantization of positively stained cells are expressed as mean number of positive cells/10 high-power field (40x) and * P < 0.05. Abbreviations: COA, coenzyme A; HBG1, hemoglobin subunit gamma 1; KEGG, Kyoto Encyclopedia of Genes and Genomes; LBP, lipopolysaccharide binding protein; LPS, lipopolysaccharide; TLR4, toll-like receptor 4;